Lundbeck US, an affiliate of Danish-based H. Lundbeck A/S, ranked first in corporate reputation among 28 leading U.S. pharmaceutical companies, according to patient groups in PatientView’s 4th annual Corporate Reputation of Pharma study.
“We are humbled and honored by this recognition from the patient groups whose input determined these study findings,” said Peter Anastasiou, President of Lundbeck US. “At Lundbeck, patient-centricity is deeply embedded in our culture, and it informs everything we do. We have worked hard to support people living with psychiatric and neurological disorders, and we are very proud of these corporate reputation survey results.”
PatientView’s study reflects the views of 106 American patient groups on six key reputational attributes: Patient-Centricity, Information, Patient Safety, Usefulness of Products, Transparency and Integrity. Lundbeck not only ranked first in overall corporate reputation and first in all six individual categories, but received some of the strongest total support in the study’s history. According to the report, “the percentages awarded Lundbeck by U.S. patient groups stand among the highest ever recorded in PatientView’s Corporate Reputation surveys.”
Among the report’s highlights:
- 83.9 percent of respondents familiar with Lundbeck US identified the company among their top three for “most effective patient-centered strategy” (50 percent ahead of the second highest ranked organization)
- 87.5 percent of the patient groups familiar with Lundbeck US report to “have had a working relationship” with the company (29 percent ahead of the second highest ranked organization)
- 62.5 percent of respondents familiar with Lundbeck US identified the company among their top three for “most integrity” (37 percent ahead of the second highest ranked organization)
Lundbeck’s engagement with patient organizations goes beyond its products and involves active participation in patient communities among hundreds of employees. Ongoing engagements include programs to support employers and community-based organizations in efforts to address individuals with mental illness, scholarship programs for patients and caregivers to attend educational conferences, volunteerism at hundreds of local non-profit events and an art therapy program for people with epilepsy called Studio E.
“The Studio E art therapy initiative is a prime example of Lundbeck’s patient-focused approach. They listened to the needs of our community and partnered with us to help turn what was a small art therapy group into a nationwide program,” said Phil Gattone, president and CEO of the Epilepsy Foundation. “As a foundation, we are a group of individuals who care deeply and are passionate about improving lives. And when you get a chance to work with another group that shares that passion, it’s a very special experience. We consider it a great privilege to work with Lundbeck.”
The PatientView survey was fielded between November 2015 and January 2016 and included 63 groups that address Lundbeck’s core area of focus: brain disorders (41 patient groups specialize in neurological diseases and 22 specialize in mental health). The study includes a mix of global, international, national, large regional and local patient groups.